Skip to main content

Table 1 Demographic and clinical characteristics of the obstructive hypertrophic cardiomyopathy patients according to gender

From: Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy

Variable

Male (n = 99)

Female (n = 62)

p value

Age (years)

45.4 ± 10.0

50.1 ± 11.5

0.008

Body mass index (kg/m2)

26.3 ± 3.4

24.6 ± 3.0

0.004

Hypertension

26 (26 %)

22 (36 %)

0.213

Diabetes mellitus

5 (5 %)

1 (2 %)

0.488

Dyslipidemia

32 (32 %)

15 (24 %)

0.27

Current smokers

57 (58 %)

2 (3 %)

<0.001

Duration of obstructive HC (months)

12 (2–48)

12 (2–48)

0.729

NYHA functional class

  

0.636

 I

4 (4 %)

5 (8 %)

 

 II

10 (10 %)

4 (7 %)

 

 III

71 (72 %)

41 (66 %)

 

 IV

14 (14 %)

12 (19 %)

 

Syncope

30 (30 %)

23 (37 %)

0.372

Family history of HC

20 (20 %)

16 (26 %)

0.406

Family history of sudden death

11 (11 %)

6 (10 %)

0.773

Systolic blood pressure (mmHg)

117.2 ± 16.1

117.5 ± 19.3

0.902

Diastolic blood pressure (mmHg)

73.8 ± 11.1

71.6 ± 11.2

0.226

Heart rate (beats/min)

68.6 ± 9.9

70.8 ± 12.8

0.252

Atrial fibrillation

7 (7 %)

6 (10 %)

0.555

Non-sustained ventricular tachycardiaa

4 (5 %)

5 (10 %)

0.433

Medications

   

 Beta-blockers

79 (80 %)

45 (73 %)

0.289

 Calcium antagonists

26 (26 %)

25 (40 %)

0.062

 Amiodarone

5 (5 %)

2 (3 %)

0.877

 ACEI/ARB

11 (11 %)

14 (23 %)

0.051

 Statins

10 (10 %)

8 (13 %)

0.583

 Aspirin

25 (25 %)

15 (24 %)

0.880

 Diuretics

4 (4 %)

5 (8 %)

0.466

Laboratory data

   

 Serum creatinine (μmol/L)

77.2 ± 11.3

60.1 ± 11.2

<0.001

 eGFR (mL/min/1.73 m2)

101.7 ± 12.8

99.8 ± 14.6

0.386

 Blood glucose (mmol/L)

4.85 ± 0.59

4.85 ± 0.62

0.978

 HbA1c (%)

5.59 ± 0.53

5.60 ± 0.52

0.993

 Total cholesterol (mmol/L)

4.62 ± 1.01

4.54 ± 1.00

0.604

 HDL cholesterol (mmol/L)

1.07 ± 0.25

1.26 ± 0.30

<0.001

 LDL cholesterol (mmol/L)

2.89 ± 0.92

2.76 ± 0.75

0.380

 Triglycerides (mmol/L)

1.69 ± 0.93

1.52 ± 0.83

0.251

 hs-CRP (mg/L)

1.25 (0.60–2.14)

0.96 (0.40–1.94)

0.318

 NT-proBNP (pmol/L)

1154.1 (775.5–1692.5)

1811.9 (869.6–2816.0)

0.002

 Serum uric acid (μmol/L)

381.2 ± 86.4

309.0 ± 69.3

<0.001

Echocardiography

   

 Systolic anterior motion

94 (95 %)

58 (94 %)

0.981

 Moderate or severe mitral regurgitation

36 (36 %)

25 (40 %)

0.614

 LVOTG at rest (mmHg)

77.9 ± 32.5

79.7 ± 32.5

0.735

 LVOTG after provocation (mmHg)b

95.7 ± 28.9

87.8 ± 15.8

0.312

 LVOTG at rest ≥30 mmHg

93 (94 %)

57 (92 %)

0.865

Cardiac magnetic resonance

   

 Left atrium diameter (mm)

39.8 ± 7.6

40.7 ± 7.9

0.483

 LV end-diastolic diameter (mm)

46.4 ± 4.1

44.7 ± 4.1

0.010

 Maximum wall thickness (mm)

23.5 ± 4.4

23.0 ± 5.4

0.543

 Maximum wall thickness ≥30 mm

8 (8 %)

5 (8 %)

0.997

 LV ejection fraction (%)

72.2 ± 7.2

72.0 ± 7.3

0.893

 LV mass (g)

180.6 ± 64.9

137.4 ± 53.3

<0.001

 LV end-diastolic volume index (mL/m2)

65.1 ± 14.1

63.9 ± 13.9

0.61

 LV end-systolic volume index (mL/m2)

18.1 ± 6.1

18.1 ± 7.0

0.976

 Stroke volume index (mL/m2)

47.0 ± 11.3

45.8 ± 9.6

0.496

 Cardiac index (L/min/m2)

3.12 ± 0.77

3.13 ± 0.81

0.925

 LV mass index (g/m2)

96.2 ± 32.1

84.4 ± 32.4

0.025

  1. Data are expressed as mean ± SD, number (percentage), or median (interquartile range)
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HC hypertrophic cardiomyopathy, HDL high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein, LDL low-density lipoprotein, LV left ventricular, LVOTG left ventricular outflow tract gradient, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association
  3. aAmbulatory 24-h Holter monitoring results were available in 127 of the 161 study patients
  4. bLVOTG was provoked in 50 of the 161 study patients
Back to article page

Biology of Sex Differences

ISSN: 2042-6410

Contact us